CD8A and cancer: To evaluate the importance of a T-cell-mediated immune response for the antitumor efficacy of NVB, we depleted CD8+ T cells using an anti-CD8 antibody in both syngeneic models of BRCA-deficient cancers and treated with vehicle or NVB.